Display options
Cite
Mussarat S, Houston KV, Parekh PJ. Recurrent, Multisubtype Posttransplant Lymphoproliferative Disorder Masquerading as Inflammatory Bowel Disease. ACG Case Rep J. 2022;9(1):e00734doi: 10.14309/crj.0000000000000734.
Mussarat, S., Houston, K. V., & Parekh, P. J. (2022). Recurrent, Multisubtype Posttransplant Lymphoproliferative Disorder Masquerading as Inflammatory Bowel Disease. ACG case reports journal, 9(1), e00734. https://doi.org/10.14309/crj.0000000000000734
Mussarat, Saad, et al. "Recurrent, Multisubtype Posttransplant Lymphoproliferative Disorder Masquerading as Inflammatory Bowel Disease." ACG case reports journal vol. 9,1 (2022): e00734. doi: https://doi.org/10.14309/crj.0000000000000734
Mussarat S, Houston KV, Parekh PJ. Recurrent, Multisubtype Posttransplant Lymphoproliferative Disorder Masquerading as Inflammatory Bowel Disease. ACG Case Rep J. 2022 Jan 10;9(1):e00734. doi: 10.14309/crj.0000000000000734. eCollection 2022 Jan. PMID: 35028325; PMCID: PMC8751774.
Copy Download .nbib Format: NLM
Share it on

ACG Case Rep J. 2022 Jan 10;9(1):e00734. doi: 10.14309/crj.0000000000000734. eCollection 2022 Jan.

Recurrent, Multisubtype Posttransplant Lymphoproliferative Disorder Masquerading as Inflammatory Bowel Disease.

ACG case reports journal

Saad Mussarat, Kevin V Houston, Parth J Parekh

Affiliations

  1. Department of Internal Medicine, Eastern Virginia Medical School, Norfolk, VA.
  2. Department of Internal Medicine, Virginia Commonwealth University Health System, Richmond, VA.
  3. Division of Gastroenterology, Department of Internal Medicine, Eastern Virginia Medical School, Norfolk, VA.

PMID: 35028325 PMCID: PMC8751774 DOI: 10.14309/crj.0000000000000734

Abstract

Posttransplant lymphoproliferative disorder (PTLD) is a severe posttransplant complication that occurs because of immunosuppression within the first year; however, recurrent PTLD or development of multiple histologic subtypes are rare. Our case demonstrates a renal transplant recipient with rare, recurrent PTLD with multiple histologic subtypes (monomorphic and polymorphic PTLD) despite a previous response to rituximab and resolution of inflammatory changes on endoscopy. It is essential that clinicians maintain a high suspicion for PTLD when caring for patients with previous transplantation and that they have a lower threshold for biopsy with endoscopic findings of nonspecific inflammatory changes.

© 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology.

Publication Types